U.S. Genomics’ DLA platform will be used to develop a test for infectious diseases.
BD (Becton, Dickinson and Company) made a $4.5 million equity investment in U.S. Genomics and entered into a collaboration to develop an infectious disease diagnostic platform.
The partnership will leverage U.S. Genomics’ DirectLinear Analysis (DLA) technology for the detection of infectious organisms in a single test.
U.S. Genomics reports that it has invested in excess of $50 million in DLA technology, which integrates labeling strategies, advanced microfluidics, and optical engineering. It enables the identification of pathogens by analyzing individual DNA molecules present in a clinical sample.
DLA has the potential to provide information such as which drugs a specific pathogen may be resistant to and which drugs could be used for most effective patient treatment, according to the companies.
